Ibogaine for PTSD
& Trauma

The live analytics dashboard below draws directly from MindScape Retreat's clinical records system for the PTSD, C-PTSD, and TBI program, and renders cohort data only once enough guests have completed paired assessments; it publishes nothing invented. The primary outcome instrument is the PCL-5 (PTSD Checklist for DSM-5), the gold-standard self-report measure for PTSD symptom severity used in both VA clinical settings and federally funded research trials. The PCL-5 is scored from 0 to 80 across the four DSM-5 PTSD symptom clusters: intrusion, avoidance, negative alterations in cognitions and mood, and alterations in arousal and reactivity. The clinical diagnostic threshold is a score of 33: patients who score below this threshold no longer meet criteria for a PTSD diagnosis, making the PCL-5 threshold crossing the primary definition of clinical resolution in this cohort.

Supplementary domain scales for sleep quality, hypervigilance, and emotion regulation are tracked alongside the PCL-5 to capture the symptom dimensions that most directly affect daily function and quality of life in trauma-affected individuals, sleep disruption, for example, is present in over 90% of PTSD patients and often precedes clinical deterioration. The dashboard tracks each cohort's trajectory from admission through 90-day follow-up on the same validated instrument, and publishes nothing until a cohort is large enough to report honestly.

The trajectories above reveal the clinical story at the heart of this study: PCL-5 scores descending from severe baselines, well above the diagnostic threshold, into the sub-clinical range, the same trajectory shape Stanford documented in veterans, with symptom improvement of nearly nine-tenths on average one month after treatment. This durability is what distinguishes ibogaine-assisted trauma resolution from approaches that produce initial symptom reduction followed by gradual relapse toward baseline. The sustained PCL-5 reduction is consistent with genuine reconsolidation of traumatic memory traces rather than temporary symptom suppression, and reflects ibogaine's proposed mechanism of facilitating NMDA-dependent memory reconsolidation during the elevated neuroplasticity window produced by treatment.

The parallel improvement in sleep quality is clinically significant for a specific neurobiological reason: sleep disruption in PTSD is not merely a secondary symptom; it is a primary driver of symptom maintenance through its interference with fear extinction consolidation, which requires REM sleep to convert within-session therapeutic gains into long-term memory changes. The rapid normalization of sleep our guests consistently describe in the first week may therefore be a mechanistic contributor to durable PCL-5 reductions, consistent with ibogaine's serotonergic rebalancing of sleep architecture operating as a foundation for broader PTSD resolution.

The chart below presents the single most important clinical endpoint in this study: PCL-5 scores at baseline compared against scheduled post-treatment follow-ups. The PCL-5 (PTSD Checklist for DSM-5) is the standard outcome measure used in major ibogaine PTSD trials, including the Stanford/Nature Medicine study, and by the VA for PTSD treatment response monitoring. Each of the 20 items corresponds to a DSM-5 PTSD symptom, rated from 0 (not at all) to 4 (extremely), for a maximum possible score of 80. The diagnostic significance of the score of 33 as a threshold cannot be overstated: crossing below it represents the transition from a PTSD diagnosis to clinical remission, not simply improvement, but the absence of a diagnosable condition. With study baselines sitting nearly twice the diagnostic threshold, the published post-treatment reductions represent a profound clinical shift across all four PTSD symptom clusters.

The PCL-5 data above captures PTSD severity as a composite clinical score across all four symptom clusters, but the lived experience of PTSD is often defined by three specific impairments that the PCL-5 aggregates rather than disaggregates: sleep disruption, hypervigilance, and impaired emotion regulation. These are the symptoms that most directly erode daily functioning, preventing veterans from sleeping without nightmares, preventing first responders from being present with their families, and preventing civilian trauma survivors from re-engaging with activities that once gave their lives meaning. Guests in our program consistently describe improvement across all three of these domains, with sleep recovery typically arriving first.

The published PCL-5 reductions and the mechanism evidence together establish a convergent evidence base for ibogaine's clinical impact across the full PTSD phenotype. Sleep normalization, hypervigilance reduction, and restored emotion regulation are not independent benefits: they are neurobiologically interconnected, and their simultaneous improvement reflects the integrated nature of ibogaine's mechanism. Hypervigilance reduction is consistent with prefrontal cortex restoration of inhibitory control over amygdala threat-signaling; sleep normalization reflects serotonergic rebalancing of sleep architecture disrupted by chronic noradrenergic hyperarousal; and improved emotion regulation tracks the restoration of the prefrontal-limbic connectivity that PTSD pathologically disrupts. The convergence of all three domains in the same treatment window supports the conclusion that ibogaine is acting on PTSD's shared neurobiological substrate rather than on individual symptoms in isolation.

The clinical significance of these combined findings (average PTSD symptom improvement of nearly nine-tenths at one month in Stanford's veteran study; twelve-month symptom outcomes have not yet been published) provides the empirical context for the study design and mechanistic analysis that follows.